Skip to main content
Premium Trial:

Request an Annual Quote

Max Planck Institute to Use Illumina s Genotyping Platform to Study Depression, Anxiety

NEW YORK, Sept. 20 (GenomeWeb News) - Researchers at the Max Planck Institute of Psychiatry in Munichwill use Illumina's whole-genome arrays to study the genetic basis of depression and anxiety, Illumina said today.

 

In the first part of the project, the scientists will genotype a large number of samples using Illumina's Sentrix Human-1 BeadChip. In the second phase, they plan to use the company's new Sentrix BeadChip to analyze over 250,000 TagSNPs derived from data of the International HapMap project.

 

The aim of the study is to identify genetic variations associated with depression and anxiety and to determine their impact on disease pathogenesis and response to psychotropic drugs.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.